Relative Strength Chart Arrowhead Pharmaceuticals, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 19:49:34 22/01/2026 GMT			5-day change	1st Jan Change
69.32 ^USD	+2.55%		+4.32%	+4.10%

01:14pm	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI

End-of-day quotes

		Sector	Change	5d. change	Varia. Jan 1.	1-year change	5-years change	Capi.	ST	MT	LT
	ARROWHEAD PHARMACEUTICALS, INC.	Bio Therapeutic Drugs	+2.24%	+4.32%	+4.10%	+250.66%	-15.79%	9.29B